Study backs microRNA use as cancer biomarkers
This article was originally published in Clinica
Executive Summary
MicroRNAs have significant potential as biomarkers that could form the basis of a diagnostic test to identify the primary tumour site in patients with cancer of unknown primary (CUP). So suggest the results of a trial conducted by Rosetta Genomics, and published online on March 23 by Nature Biotechnology.